Dr. Truong Nguyen

Dr. Truong Nguyen Let's beat cancer sooner! Hãy cùng nhau đẩy lùi căn bệnh ung thư! Our Vision
We want to live in a world where no one develops a preventable cancer.

Our Mission
We champion the latest and most authoritative scientific research from around the world on cancer prevention and survival through diet, weight and physical activity, from single to multi target drugs in cancer therapy, so that we can help people make informed choices to reduce their cancer risk. As a network, we influence policy at the highest level and are trusted advisors to governments and to other official bodies from around the world.

🧬 Đột phá mới trong điều trị ung thư vú tiến triển HR+/HER2-: Liệu pháp kết hợp Gedatolisib mang lại hiệu quả vượt trội!...
29/07/2025

🧬 Đột phá mới trong điều trị ung thư vú tiến triển HR+/HER2-: Liệu pháp kết hợp Gedatolisib mang lại hiệu quả vượt trội! 🎯

💡 Một tin vui từ thử nghiệm lâm sàng pha 3 VIKTORIA-1 vừa được công bố: liệu pháp kết hợp thuốc nhắm trúng đích Gedatolisib đã đạt được kết quả rất ấn tượng ở nhóm bệnh nhân ung thư vú tiến triển HR+/HER2- mang kiểu gen PIK3CA hoang dã (wild-type).

📊 Kết quả nổi bật:

🔹 Phác đồ 3 thuốc (Triplet):
➡️ Bao gồm Gedatolisib + Palbociclib + Fulvestrant
✅ Giảm nguy cơ bệnh tiến triển hoặc tử vong đến 76% so với chỉ dùng fulvestrant
📈 Thời gian sống không bệnh tiến triển (mPFS) tăng từ 2.0 tháng ➡️ 9.3 tháng
📉 HR = 0.24 (95% CI: 0.17–0.35); P < 0.0001

🔹 Phác đồ 2 thuốc (Doublet):
➡️ Bao gồm Gedatolisib + Fulvestrant
✅ Giảm nguy cơ bệnh tiến triển hoặc tử vong 67% so với chỉ dùng fulvestrant
📈 mPFS tăng từ 2.0 tháng ➡️ 7.4 tháng
📉 HR = 0.33 (95% CI: 0.24–0.48); P < 0.0001

🩺 Điều gì làm kết quả này trở nên đặc biệt?
🌟 Đây là lần đầu tiên một liệu pháp trong nhóm HR+/HER2- có thể đạt được mức cải thiện PFS lên đến 9.3 tháng ở nhóm PIK3CA wild-type — một nhóm vốn chưa có liệu pháp nhắm trúng đích chuyên biệt.
🛡️ Thêm vào đó, tác dụng phụ liên quan đến điều trị thấp hơn so với các thử nghiệm thuốc được phê duyệt hiện nay, với tỷ lệ thấp hơn về tăng đường huyết và viêm niêm mạc miệng.

💬 Thông điệp hy vọng:
Việc bổ sung Gedatolisib vào phác đồ điều trị đã mở ra một cơ hội sống mới cho bệnh nhân HR+/HER2- ABC – một dạng ung thư vú tiến xa có tiên lượng thường rất hạn chế.

🧪 Dữ liệu đầy đủ từ nhánh PIK3CA wild-type của thử nghiệm VIKTORIA-1 sẽ tiếp tục được trình bày tại các hội nghị khoa học lớn trong thời gian tới.

⸻

📌 Nguồn: Celcuity Inc. - Thông cáo báo chí ngày 28/07/2025
💗🧬

“NEW STUDY – Ivermectin Shows Striking Anticancer Potential and Remarkable Safety”Nicolas Hulscher, MPH (Published April...
24/07/2025

“NEW STUDY – Ivermectin Shows Striking Anticancer Potential and Remarkable Safety”

Nicolas Hulscher, MPH (Published April 23, 2025):

🎯 Study Objective

This systematic review aimed to assess:
1. The clinical safety of ivermectin in cancer patients (based on its use for parasitic infections).
2. The preclinical anticancer activity of ivermectin from lab and animal studies.

📚 Study Overview
• Out of 2,273 publications, 26 studies met the criteria.
• Included 36 cancer patients who received oral ivermectin (mostly for treating parasites, not cancer).
• Although not designed to evaluate antitumor effects, several anecdotal improvements were reported.

🛡️ Clinical Safety
• Ivermectin was consistently well tolerated.
• No serious adverse events were linked to its use.
• Mild side effects (e.g., gastrointestinal discomfort, transient rash) were non-specific and self-resolving.
• Used safely in patients undergoing:
• Chemotherapy
• Hematologic cancers (e.g., leukemia, lymphoma)
• Solid tumors (e.g., breast, cervical, renal)

📈 Cancer-Related Observations (Anecdotal Reports)
• 🧒 Pediatric Acute Lymphoblastic Leukemia (ALL):
A 6-year-old boy remained in long-term remission after ivermectin treatment for Demodex folliculorum.
• 🧓 Acute Myeloid Leukemia (AML):
Patient with scabies during chemotherapy had complete resolution after ivermectin; remained clinically stable.
• ⚪ Other hematologic malignancies:
Skin conditions improved rapidly; short-term stability noted after ivermectin.
• 🧬 Adult T-cell Leukemia/Lymphoma (ATL):
A patient stabilized after combination ivermectin + chemotherapy (causal role unclear).

⚙️ Preclinical Antitumor Mechanisms

Studies in cells and animal models show ivermectin suppresses tumors via:
• 🚫 Inhibiting YAP1 nuclear translocation
• ❌ Blocking Wnt/TCF signaling
• 🔻 Degrading PAK1
• 🔒 Inhibiting AKT/mTOR pathway
• ⚡ Inducing mitochondrial dysfunction & oxidative stress
• ☠️ Triggering caspase-dependent apoptosis

These effects were observed in:
• Glioblastoma
• Ovarian cancer
• Chronic myeloid leukemia (CML)
• Cervical cancer

✅ Conclusion
• Ivermectin is safe in cancer patients, even during active chemotherapy.
• Multiple preclinical anticancer mechanisms and anecdotal improvements suggest repurposing ivermectin as an oncology drug is promising.
• Urgent need for well-designed, large-scale clinical trials to assess its therapeutic value in cancer treatment.

🔎 Cập nhật Quản lý Tăng Huyết Áp - Phiên bản 2025📚 Thông tin lâm sàng mới nhất & Cách tiếp cận thực tiễn 🫀🧠⸻📌 1. Tiêu c...
11/07/2025

🔎 Cập nhật Quản lý Tăng Huyết Áp - Phiên bản 2025

📚 Thông tin lâm sàng mới nhất & Cách tiếp cận thực tiễn 🫀🧠

⸻

📌 1. Tiêu chuẩn Chẩn đoán (JNC 8 + ACC/AHA)
🩺 Đo ≥2 lần trong ≥2 dịp khác nhau
🏠 Khuyến khích đo tại nhà hoặc theo dõi huyết áp 24h (để loại trừ THA áo choàng trắng)

💖 Phân loại 💉 Chỉ số Huyết áp (mmHg)
🟢 Bình thường:

🔬🧠 Cracking a Major Mystery in Pancreatic Cancer!🧬 Although KRAS mutations are widespread in early pancreatic lesions, m...
07/07/2025

🔬🧠 Cracking a Major Mystery in Pancreatic Cancer!

🧬 Although KRAS mutations are widespread in early pancreatic lesions, most never progress to cancer. Why?

🧪 A groundbreaking study in Nature Cancer (led by Laura Antonucci and the Karin lab – UCSD) has identified the missing link:
🔥 Oxidative stress → epigenetically reprograms KRAS-mutant cells
🔁 via a self-reinforcing NRF2–EZH2 loop
⚠️ This drives irreversible malignant transformation, even without additional mutations.

💡 This explains how inflammation and stress accelerate pancreatic cancer and reveals a vulnerability in the earliest stage of tumor evolution.

🚨 Targeting the NRF2–EZH2 axis could open a new path to intercept pancreatic cancer before it turns clinically aggressive — a potentially transformative approach for early intervention.

👨‍🔬 We at the Moscat/Diaz-Meco lab, Weill Cornell Medicine, are proud to be part of this highly collaborative and impactful study!

📖 Read more: https://lnkd.in/dZXFnnk5


https://media.licdn.com/dms/image/v2/D4D22AQFDnSgLNUok-A/feedshare-shrink_800/B4DZfQABHTHkAo-/0/1751541356103?e=1754524800&v=beta&t=lBoSCmbIrGRVrbblPm1W8BPf-_0ggv0kIb67EGLXGgM

🧪🔁🧬

CÓ GÌ MỚI TẠI HỘI NGHỊ HỘI UNG THƯ HỌC LÂM SÀNG CHÂU ÂU ESMO 2025🔥 TALENTACE – Nghiên cứu giai đoạn III mở ra hướng mới ...
04/07/2025

CÓ GÌ MỚI TẠI HỘI NGHỊ HỘI UNG THƯ HỌC LÂM SÀNG CHÂU ÂU ESMO 2025

🔥 TALENTACE – Nghiên cứu giai đoạn III mở ra hướng mới cho HCC trung gian - nặng!

Tại GI 2025, nghiên cứu TALENTACE pha III đã được công bố, so sánh TACE kết hợp Atezolizumab + Bevacizumab so với TACE đơn thuần ở bệnh nhân ung thư gan không thể phẫu thuật, gánh nặng khối u trung bình đến cao (BCLC-B và BCLC-C cho Vp1/2).

🔍 Kết quả nổi bật:
✅ ORR: 49% vs 34%
✅ Trung vị PFS: 11.3 tháng vs 7.03 tháng
✅ Trung vị OS: 34 tháng vs 35 tháng (dữ liệu OS chưa kết thúc)
⚠️ PFS cải thiện rõ rệt – đầy hứa hẹn!

🎯 Nghiên cứu nhấn mạnh vai trò của miễn dịch kết hợp kháng sinh mạch trước can thiệp TACE – hướng đi tiềm năng để tối ưu hiệu quả cho nhóm bệnh nhân HCC trung gian có tải khối u cao.



🔥 TALENTACE Phase III – New Frontiers in Intermediate-to-High Burden HCC!

Just out at GI 2025 – the TALENTACE Phase III trial compared on-demand TACE + atezolizumab + bevacizumab vs TACE alone in patients with unresectable intermediate-to-advanced HCC (BCLC-B/C with Vp1/2, no extrahepatic spread).

📊 Key Highlights:
✅ ORR: 49% vs 34%
✅ Median PFS: 11.3 vs 7.03 months
✅ Median OS: 34 vs 35 months (OS not mature yet)
⚠️ PFS benefit is clinically meaningful!

💡 This study emphasizes the potential of IO + anti-VEGF combination prior to TACE in intermediate HCC patients with a high tumor burden – a new therapeutic strategy worth watching.

Incredibly encouraging” first results of Terbium prostate cancer therapy.
03/07/2025

Incredibly encouraging” first results of Terbium prostate cancer therapy.

Overview of Cancer of the Ampulla of Vater📌 OverviewAmpullary cancer is a rare gastrointestinal malignancy, accounting f...
03/07/2025

Overview of Cancer of the Ampulla of Vater

📌 Overview

Ampullary cancer is a rare gastrointestinal malignancy, accounting for 0.2–0.5% of all GI cancers and approximately 0.49 cases per 100,000 population.
It arises from the Ampulla of Vater, the anatomical site where the common bile duct and pancreatic duct converge and drain into the duodenum.

🔍 Clinical Presentation

Due to its strategic location, ampullary cancer often causes early symptoms:
- Obstructive jaundice (yellow skin, dark urine, pale stools)
- Itching, abdominal pain, nausea or vomiting (duodenal obstruction)
- Gastrointestinal bleeding (less common)
- Weight loss, fatigue, or anorexia

🧪 Diagnostic Workup

Blood tests: Elevated bilirubin, GGT, ALP. Tumor markers:
* CA 19-9 (sensitive for pancreatic origin)
* CEA (often elevated in biliary cancers)
* Combined marker assessment increases diagnostic accuracy (\~86%)

🩻Imaging:

* Ultrasound: Detects biliary dilation
* CT scan: Assesses lymph nodes, metastasis
* MRI with contrast (≥1.5T): Best for detailed anatomy and soft tissue contrast
* MRCP / ERCP: Visualizes biliary tree; allows for biopsy
* Endoscopic biopsy (via ERCP or endoscopic ultrasound) is the gold standard for diagnosis.

🧬 Histopathology
* Most are adenocarcinomas
* Two main subtypes:
1. Intestinal type – better prognosis
2. Pancreatobiliary type – poorer prognosis

🛠️ Treatment
* Surgical resection (Whipple procedure – pancreaticoduodenectomy) is the treatment of choice if operable.
* If not resectable:
- Palliative surgery: e.g., biliary bypass
- Stenting to relieve obstruction
* Adjuvant chemotherapy or chemoradiation may be considered based on staging and pathology.

📈 Prognosis
* Survival highly depends on stage, lymph node status, and histological subtype.
* 5-year survival rate after complete surgical resection ranges from 20% to 75%
* Better for intestinal-type tumors and early-stage disease

✅ Conclusion
Although rare, ampullary cancer often presents early due to biliary obstruction, giving it a better prognosis than pancreatic or biliary cancers.
Prompt diagnosis via imaging and biopsy, followed by surgical intervention, is key to improving long-term outcomes.

of the Ampulla of Vater

🧬 Unlocking a New Era in Multiple Myeloma Treatment – ASCO 2025 Highlights💥ASCO 2025 delivered an abundance of practice-...
03/07/2025

🧬 Unlocking a New Era in Multiple Myeloma Treatment – ASCO 2025 Highlights💥

ASCO 2025 delivered an abundance of practice-changing data across solid tumors like breast, lung, gastroesophageal, and head & neck cancers. But one groundbreaking abstract in hematologic oncology didn’t get the spotlight it truly deserved.

🌟 CARVYKTI (ciltacabtagene autoleucel) – Johnson & Johnson’s CAR-T therapy – may have just redefined outcomes in relapsed/refractory multiple myeloma (RRMM):

📌 Key CARTITUDE-1 results:
🔹 33% of heavily pretreated patients (≥3 prior lines) remained progression-free for at least 5 years after just one infusion
🔹 Median overall survival: 60.7 months
(Compared to \~12 months with standard therapies)

🧠 This data pushes us to rethink treatment goals in RRMM — from chronic control to durable, off-therapy remission.

👉 Additional findings from CARTITUDE-4 support earlier use of Carvykti, with 70% of standard-risk patients progression-free beyond 3 years.

🌍 With over 6,500 patients treated globally, Carvykti is now at the forefront of CAR-T innovation, having surpassed its closest competitor Abecma.

⚔️ But competition is heating up — GSK’s Blenrep (belantamab mafodotin) is re-entering the space with impressive DREAMM-7 and -8 data. Its outpatient convenience is appealing, but efficacy and safety remain key — especially considering ocular toxicity risks.

🔄 The multiple myeloma landscape is shifting fast, offering renewed hope and options for patients and providers alike.

🤔 How do you think these advances will shape future myeloma R\&D and care strategies? Share your thoughts below!

\

💥 Exciting news from ESMO Gynae 2025! 💥Adding atezolizumab to chemotherapy + bevacizumab has previously shown to improve...
20/06/2025

💥 Exciting news from ESMO Gynae 2025! 💥

Adding atezolizumab to chemotherapy + bevacizumab has previously shown to improve progression-free survival (PFS) and overall survival (OS) in patients with recurrent/metastatic cervical cancer who hadn’t received prior treatment, according to the BEAT trial 🔬💉

📊 A new analysis from BEATcc, presented at , shows similar PFS and OS benefits with the triple combination regardless of PD-L1 status!
🟢 PFS HR = 0.54 in patients with PD-L1 CPS ≥1
🔵 PFS HR = 0.48 in patients with PD-L1 CPS

Address

350/8 Le Van Sy, Ward 14
Quận 3
72409

Telephone

+84908855557

Website

Alerts

Be the first to know and let us send you an email when Dr. Truong Nguyen posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Dr. Truong Nguyen:

Shortcuts

Share

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram

Category